<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ871104-0046 </DOCNO><HL> Business Brief:Viratek Inc.</HL><DD> 11/04/87</DD><SO> WALL STREET JOURNAL (J)</SO><IN> VIRA EUROPPHARMACEUTICALS, HOSPITAL SUPPLIES, MANAGEMENT (PHA) </IN><TEXT>   Viratek Inc., a Costa Mesa, Calif., pharmaceutical concern, said its anti-viral drug Virazole has been approved by United Kingdom health authorities for treatment of children with acute bronchiolitis caused by respiratory syncytial virus, or RSV.    The company said approval was based on clinical studies conducted in Scotland, London and the U.S. Virazole is currently sold for the treatment of RSV in hospitalized infants and young children in the U.S. and Canada. </TEXT></DOC>